X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2444) 2444
Publication (206) 206
Newsletter (29) 29
Book Review (23) 23
Book Chapter (7) 7
Magazine Article (5) 5
Conference Proceeding (4) 4
Paper (3) 3
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fenofibrate (1395) 1395
humans (1064) 1064
fenofibrate - pharmacology (1048) 1048
male (1037) 1037
index medicus (1016) 1016
animals (964) 964
pharmacology & pharmacy (926) 926
hypolipidemic agents - pharmacology (605) 605
female (520) 520
rats (483) 483
mice (426) 426
fenofibrate - therapeutic use (424) 424
middle aged (402) 402
hypolipidemic agents - therapeutic use (318) 318
adult (291) 291
ppar alpha - agonists (243) 243
triglycerides - blood (242) 242
ppar-alpha (240) 240
fenofibrate - administration & dosage (235) 235
cholesterol (233) 233
ppar alpha - metabolism (218) 218
aged (217) 217
liver - metabolism (203) 203
biochemistry & molecular biology (200) 200
metabolism (199) 199
solubility (195) 195
lipids (192) 192
expression (187) 187
liver - drug effects (186) 186
fenofibrate - chemistry (185) 185
atherosclerosis (175) 175
cholesterol - blood (160) 160
rats, sprague-dawley (159) 159
fenofibrate - analogs & derivatives (158) 158
fibric acids (158) 158
hypolipidemic agents - administration & dosage (156) 156
dyslipidemia (151) 151
lipids - blood (150) 150
rats, wistar (149) 149
fenofibrate - pharmacokinetics (148) 148
inflammation (147) 147
mice, inbred c57bl (147) 147
cells, cultured (143) 143
endocrinology & metabolism (142) 142
hyperlipidemias - drug therapy (141) 141
gemfibrozil (137) 137
gene-expression (137) 137
cardiac & cardiovascular systems (135) 135
dose-response relationship, drug (135) 135
drugs (135) 135
diabetes (133) 133
liver (133) 133
coronary-heart-disease (128) 128
risk factors (127) 127
oxidative stress (125) 125
metabolic syndrome (124) 124
analysis (122) 122
drug therapy, combination (122) 122
statins (122) 122
atorvastatin (121) 121
triglycerides (121) 121
bioavailability (119) 119
fenofibrate - adverse effects (119) 119
research (119) 119
chemistry, medicinal (118) 118
peripheral vascular disease (118) 118
dissolution (117) 117
cholesterol, hdl - blood (116) 116
article (115) 115
fibrates (115) 115
hyperlipidemia (115) 115
simvastatin (114) 114
disease models, animal (112) 112
insulin resistance (112) 112
cholesterol, ldl - blood (111) 111
rna, messenger - metabolism (110) 110
pharmacology/toxicology (109) 109
dyslipidemias - drug therapy (106) 106
hypolipidemic agents - adverse effects (106) 106
time factors (106) 106
treatment outcome (106) 106
medicine, research & experimental (104) 104
medicine & public health (103) 103
cardiovascular-disease (102) 102
risk (100) 100
gene expression regulation - drug effects (99) 99
ppar alpha - genetics (97) 97
hypolipidemic agents - chemistry (95) 95
drug delivery systems (94) 94
therapy (94) 94
toxicology (94) 94
particle size (92) 92
type-2 diabetes-mellitus (92) 92
hypolipidemic agents - pharmacokinetics (91) 91
insulin-resistance (89) 89
obesity (89) 89
thiazolidinediones - pharmacology (89) 89
chemistry, multidisciplinary (88) 88
disease (88) 88
double-blind method (88) 88
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2411) 2411
Chinese (23) 23
French (18) 18
Japanese (17) 17
Russian (6) 6
German (5) 5
Spanish (4) 4
Polish (2) 2
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Pharmacology, ISSN 0007-1188, 11/2007, Volume 152, Issue 5, pp. 734 - 743
Background and purpose: Although CB1 receptor activation evokes neuroprotection in response to cannabinoids, some cannabinoids have been reported to be... 
Neuroprotection | Peroxisome proliferator-activated receptors (PPARs) | Cannabinoids | N-oleoylethanolamine | GAMMA | CELLS | FOCAL CEREBRAL-ISCHEMIA | ANANDAMIDE | ENDOCANNABINOID SYSTEM | NUCLEAR RECEPTOR | peroxisome proliferator-activated receptors (PPARs) | neuroprotection | cannabinoids | THERAPEUTIC TARGETS | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | TRANSCRIPTION FACTOR | BRAIN | Luciferases - metabolism | Humans | Benzoxazines - metabolism | Male | Recombinant Fusion Proteins - metabolism | Cerebral Cortex - metabolism | Neuroprotective Agents - metabolism | Luciferases - genetics | Oleic Acids - metabolism | Arachidonic Acids - metabolism | Fenofibrate - pharmacology | Neuroprotective Agents - pharmacology | Transfection | I-kappa B Kinase - metabolism | Cerebral Cortex - drug effects | Oleic Acids - pharmacology | Dronabinol - pharmacology | Naphthalenes - metabolism | Cannabinoids - metabolism | Endocannabinoids | Fenofibrate - metabolism | Mice, Inbred C57BL | Morpholines - pharmacology | Fatty Acids, Unsaturated - pharmacology | Morpholines - metabolism | PPAR alpha - genetics | Polyunsaturated Alkamides - metabolism | Arachidonic Acids - pharmacology | Cannabinoids - pharmacology | Mice, Knockout | Naphthalenes - pharmacology | Animals | Benzoxazines - pharmacology | Cyclooxygenase 2 - metabolism | Polyunsaturated Alkamides - pharmacology | Protein Binding | Recombinant Fusion Proteins - genetics | Ligands | PPAR alpha - agonists | Mice | HeLa Cells | PPAR alpha - metabolism | Dronabinol - metabolism | Research Papers
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 06/2007, Volume 27, Issue 6, pp. 1276 - 1282
OBJECTIVE—Activation of peroxisome proliferator-activated receptors (PPARs) by lipid-lowering fibrates and insulin-sensitizing thiazolidinediones inhibits... 
Inflammation | PPAR | Atherosclerosis | Heme oxygenase | atherosclerosis | heme oxygenase | LIPID-METABOLISM | PPAR-ALPHA ACTIVATORS | 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J | DEPENDENT PATHWAY | RESPONSIVE ELEMENT | PLASMA-CHOLESTEROL | inflammation | INTIMAL HYPERPLASIA | ENDOTHELIAL-CELLS | GENE-EXPRESSION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | MICROSATELLITE POLYMORPHISM | Tumor Necrosis Factor-alpha - metabolism | Transcription, Genetic - drug effects | Cell Proliferation | Humans | Protoporphyrins - pharmacology | PPAR gamma - metabolism | Metalloporphyrins - pharmacology | Cyclooxygenase 2 - biosynthesis | Dose-Response Relationship, Drug | Heme Oxygenase-1 - genetics | RNA, Messenger - biosynthesis | Fenofibrate - pharmacology | Transfection | Chromans - pharmacology | Time Factors | Myocytes, Smooth Muscle - drug effects | Thiazolidinediones - pharmacology | Muscle, Smooth, Vascular - drug effects | PPAR gamma - genetics | Promoter Regions, Genetic | Heme Oxygenase-1 - biosynthesis | Anti-Inflammatory Agents - pharmacology | Myocytes, Smooth Muscle - enzymology | Cells, Cultured | Enzyme Inhibitors - pharmacology | Enzyme Induction | PPAR alpha - genetics | Pyrimidines - pharmacology | Muscle, Smooth, Vascular - cytology | Heme Oxygenase-1 - antagonists & inhibitors | Polymorphism, Genetic | Membrane Proteins - biosynthesis | PPAR gamma - agonists | PPAR alpha - agonists | Mutation | PPAR alpha - metabolism | Endothelial Cells - enzymology | Muscle, Smooth, Vascular - enzymology | Endothelial Cells - drug effects
Journal Article
Journal Article
Inflammation, ISSN 0360-3997, 2/2014, Volume 37, Issue 1, pp. 177 - 185
Journal Article
Journal Article
Experimental Cell Research, ISSN 0014-4827, 06/2013, Volume 319, Issue 10, pp. 1523 - 1533
Journal Article
Pharmaceutical Biology, ISSN 1388-0209, 09/2016, Volume 54, Issue 9, pp. 1705 - 1715
Context Fibrates were reported to have anti-inflammatory effects while the naturally occurring polyphenol resveratrol was traditionally known as a potent... 
dexamethasone | complete Freund's adjuvant | methotrexate | antioxidant | immuno-modulatory | Anti-inflammatory | complete Freund’s adjuvant | COLLAGEN-INDUCED ARTHRITIS | OXIDATIVE STRESS | PROINFLAMMATORY CYTOKINES | ANTINUCLEAR ANTIBODIES | PLANT SCIENCES | ISCHEMIA-REPERFUSION INJURY | FIBROBLAST-LIKE SYNOVIOCYTES | MATRIX METALLOPROTEINASES | TUMOR-NECROSIS-FACTOR | PHARMACOLOGY & PHARMACY | MEDICAL LABORATORY TECHNOLOGY | AUTOIMMUNE-DISEASE | ADJUVANT ARTHRITIS | Methotrexate - pharmacology | Rats, Wistar | Spleen - drug effects | Stilbenes - pharmacology | Fenofibrate - pharmacology | Dexamethasone - pharmacology | Arthritis, Experimental - chemically induced | Arthritis, Experimental - prevention & control | Female | Anti-Inflammatory Agents - isolation & purification | Antirheumatic Agents - pharmacology | Spleen - pathology | Immunosuppressive Agents - pharmacology | Joints - metabolism | Cytokines - blood | Arthritis, Experimental - blood | Anti-Inflammatory Agents - pharmacology | Joints - drug effects | Inflammation Mediators - blood | Joints - pathology | Arthritis, Experimental - immunology | Antioxidants - pharmacology | Biomarkers - blood | Freund's Adjuvant | Animals | Spleen - metabolism | Antioxidants - isolation & purification | Antirheumatic Agents - isolation & purification | Immunosuppressive Agents - isolation & purification | Oxidative Stress - drug effects | Index Medicus
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 04/2009, Volume 156, Issue 8, pp. 1206 - 1215
Background and purpose:  Statins and fibrates can produce mild to life-threatening skeletal muscle damage. Resting chloride channel conductance (gCl), carried... 
skeletal muscle | chloride channel | gene expression | cell signaling | hypolipidemic drugs | Chloride channel | Hypolipidemic drugs | Gene expression | Cell signaling | Skeletal muscle | PROTEIN-KINASE-C | COA REDUCTASE INHIBITORS | ACID | MANAGEMENT | DECREASE | MYOPATHY | EXERCISE | MYOTONIA | IN-VIVO | PHARMACOLOGY & PHARMACY | MODULATION | Fatty Acids, Monounsaturated - pharmacology | Chloride Channels - drug effects | Rats, Wistar | Calcium - metabolism | Humans | Male | Muscle, Skeletal - metabolism | Chloride Channels - genetics | RNA, Messenger - metabolism | Action Potentials | Dose-Response Relationship, Drug | Fenofibrate - pharmacology | Transfection | Protein Kinase C - metabolism | Chlorides - metabolism | Muscle, Skeletal - drug effects | Indoles - pharmacology | Electromyography | Fatty Acids, Monounsaturated - toxicity | Heptanoic Acids - pharmacology | Cell Line | Hydroxymethylglutaryl-CoA Reductase Inhibitors - toxicity | Down-Regulation | Rats | Indoles - toxicity | Protein Kinase C - antagonists & inhibitors | Hypolipidemic Agents - pharmacology | Benzophenanthridines - pharmacology | Chloride Channels - metabolism | Atorvastatin Calcium | Heptanoic Acids - toxicity | Patch-Clamp Techniques | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Pyrroles - toxicity | Hypolipidemic Agents - toxicity | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Fenofibrate - toxicity | Index Medicus | Research Papers With Commentaries
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2014, Volume 16, Issue 6, pp. 537 - 544
Journal Article